CA3174413A1 - Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast - Google Patents

Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast Download PDF

Info

Publication number
CA3174413A1
CA3174413A1 CA3174413A CA3174413A CA3174413A1 CA 3174413 A1 CA3174413 A1 CA 3174413A1 CA 3174413 A CA3174413 A CA 3174413A CA 3174413 A CA3174413 A CA 3174413A CA 3174413 A1 CA3174413 A1 CA 3174413A1
Authority
CA
Canada
Prior art keywords
cancer
day
ibudilast
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174413A
Other languages
English (en)
French (fr)
Inventor
Yuichi Iwaki
Kazuko Matsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3174413A1 publication Critical patent/CA3174413A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3174413A 2020-04-06 2021-04-05 Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast Pending CA3174413A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005792P 2020-04-06 2020-04-06
US63/005,792 2020-04-06
PCT/US2021/025732 WO2021207054A1 (en) 2020-04-06 2021-04-05 Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast

Publications (1)

Publication Number Publication Date
CA3174413A1 true CA3174413A1 (en) 2021-10-14

Family

ID=75674991

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174413A Pending CA3174413A1 (en) 2020-04-06 2021-04-05 Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast

Country Status (6)

Country Link
US (2) US12213966B2 (https=)
EP (1) EP4132521A1 (https=)
JP (1) JP2023521030A (https=)
CN (1) CN115335049A (https=)
CA (1) CA3174413A1 (https=)
WO (1) WO2021207054A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745814C1 (ru) * 2020-06-05 2021-04-01 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция левилимаба и ее применение
CA3226898A1 (en) 2021-07-26 2023-02-02 Kazuko Matsuda Ibudilast for preventing eye cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
WO2023150093A1 (en) * 2022-02-01 2023-08-10 Medicinova, Inc. Ibudilast for use in the treatment of post-covid conditions
JP2025523822A (ja) * 2022-07-13 2025-07-25 メディシノバ・インコーポレイテッド イブジラストの注射用製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1106178T3 (da) 1998-08-10 2005-02-28 Kyorin Seiyaku Kk Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose
SG148198A1 (en) 2003-11-21 2008-12-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
MX2007006777A (es) 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
CA2653345A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
CA2970273C (en) 2007-07-11 2020-04-14 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
US20110028510A1 (en) * 2009-02-18 2011-02-03 Combinatorx (Singapore) Pte. Ltd. Compositions, Methods, and Kits for Treating Influenza Viral Infections
EP3558301A4 (en) * 2016-12-22 2020-07-29 MediciNova, Inc. METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST
CA3023014C (en) * 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
US20190247369A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients

Also Published As

Publication number Publication date
US12213966B2 (en) 2025-02-04
JP2023521030A (ja) 2023-05-23
EP4132521A1 (en) 2023-02-15
CN115335049A (zh) 2022-11-11
US20250221969A1 (en) 2025-07-10
WO2021207054A1 (en) 2021-10-14
US20210308109A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US12213966B2 (en) Methods of reducing plasma level of macrophage migratory inhibitory factor in patients
CN101848712B (zh) 用异丁地特治疗渐进性神经变性疾病
AU2023233115A1 (en) Methods of treating eosinophilic esophagitis
US20210177812A1 (en) Methods of suppressing myeloid-derived suppressor cells in patients
US11865214B2 (en) Ibudilast oral formulations and methods of using same
US12171752B2 (en) Methods of treating post-COVID condition(s)
US12005049B2 (en) Methods of preventing cancer metastasis
US20230090534A1 (en) Methods of treating glioblastoma multiforme using combination therapy
US12042485B2 (en) Methods of minimizing cancer metastasis
EP3866788B1 (en) Treatment of macular injury associated with multiple sclerosis with ibudilast
EP3863628B1 (en) Combination of ibudilast and interferon-beta and methods of using same
Zarogoulidis et al. Modification Tadalafil and Macitentan tablets to aerosol
US20260069545A1 (en) Modified release formulations of ibudilast
AU2022324695A1 (en) Treatment of non-cystic fibrosis bronchiectasis
WO2012103116A1 (en) Pulmonary administration of rifalazil and analogs thereof
HK1147953A (en) Treatment of progressive neurodegenerative disease with ibudilast

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250304

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250304

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250304

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250407

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250408

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250505

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250505

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250505

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250520

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260210

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260303